Hedia and Glooko have released a solution interoperable system that combines remote patient monitoring, connected care and digital technologies. It aims to improve care for people with diabetes type 1 and type 2 who require advanced support for bolus insulin dosing.
This solution is currently available in the UK and will soon be available in other European countries.
An insulin bolus is an extra dose that covers increases in blood glucose related to meals or snacks.This type of dosage is also used to correct high blood sugar levels. Typically, one unit of insulin lowers blood glucose by 50 mg/dl, but this effect varies from person to person.
The complexity of calculating the bolus dose
For those without an insulin pump, calculating the appropriate bolus dose can be a significant challenge. Both patients and physicians face difficulties in adjusting these doses, especially in multiple daily injection (MDI) settings.
The integration of Hedia Diabetes Assistant with the Glooko platform aims to solve this challenge. Hedia offers patients personalized support to calculate their insulin doses accurately. This simplifies diabetes management and promotes more consistent blood glucose levels.
Benefits for patients and healthcare providers
Through the Glooko platform, patients can share key data about their diabetes management with their healthcare providers. This data includes blood glucose readings, insulin doses, carbohydrate intake, physical activity, blood pressure, and weight.
For their part, care providers gain a more complete and detailed view of their patients’ health. This improves decision-making and enables a streamlined approach to administering MDI therapy, both in remote and in-person settings. This integration facilitates personalized care and helps stabilize glucose levels.
Mike Alvarez, CEO of Glooko, highlighted the importance of this solution. “With extensive clinical data supporting the efficacy of Hedia, this tool offers an alternative for those without access to insulin pumps. It ensures more effective management of MDI therapy. This partnership reflects our commitment to promoting digital tools that optimize diabetes care.”
Lars Christian Lund, CEO of Hedia, expressed enthusiasm for this partnership. “We are delighted to partner with Glooko, a digital health company with an extensive clinical network. Our joint offering is aligned with Hedia’s vision of improving the quality of life of people with diabetes. In addition, our MDR certification in Europe and our designation as a class IIb medical device ensure that patients and care teams receive the best solutions available.”
A promising solution
This partnership between Hedia and Glooko not only offers technological innovation, but also more accessible and personalized care for those facing the challenges of daily diabetes management. Backed by robust clinical data and a commitment to regulation, this collaboration marks a significant advancement in diabetes care.
